At the completion of the meeting the participants should: 1) be able to discuss mechanisms that regulate tolerance and autoimmunity; 2) understand how organ specific and systemic autoimmune diseases arise; 3) understand the rational for the use of biologics (for example anti-TNF, IL-1 inhibitors), drugs (for example cyclosporin, FK506) and gene therapy in the treatment of autoimmune diseases; 4) plan research that will improve the welfare of patients with autoimmune diseases; 5) deliver better care to patients with organ specific and systemic autoimmune diseases.